Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data ...

Shares of Larimar Therapeutics, Inc.. (NASDAQ:LRMR) rose sharply in today's pre-market trading after the company announced ...

Larimar (LRMR) said the FDA has removed a partial clinical hold on its nomlabofusp clinical program following a review of ...

(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...

Leerink Partners raised the price target for the Larimar Therapeutics Inc (NASDAQ:LRMR) stock to “an Outperform”. The rating was released on April 03, 2024, according to finviz. The research report ...

Larimar Therapeutics (LRMR) surged more than +21% in pre-market trading following the announcement that the FDA lifted a partial clinical hold on the company’s nomlabofusp clinical program after ...

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report), retaining the price ...

By Stephen Nakrosis Shares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration ...

First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 ...

BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $14.7 million in its first quarter. On a per-share basis, the Bala Cynwyd, Pennsylvania ...

Real-time index price for S&P 500 Consumer Discretionary [Sector] (SRCD), along with buy or sell indicators, analysis, charts, historical performance, news and more ...